Intestinal Rehabilitation and Transplant Association Update


As reported previously in the Tribune, the endorsement by the IRTA membership for the change in the name of our Association took place at the 2015 Congress in Buenos Aires, Argentina. The new name more accurately reflects the commitment of our Association to multidisciplinary education and research along the entire continuum of care for patients with intestinal failure. We are now actively planning the next meeting of IRTA and we ask that you mark your calendars, prepare your most significant observations and discoveries for abstract and poster presentations and plan to attend the Congress of the Intestinal Rehabilitation and Transplant Association (CIRTA 2017) in New York City June 28 – July 1, 2017. Please visit the Congress website for more information about the exciting program that is planned.

The morning air is crisp signifying the welcomed transition of the season from summer to fall. Like the change of seasons (and in addition to the name change), our Association is undergoing a subtle, but no less profound transformation. One of the signature functions of our Association has long been the summary of the world experience in intestinal transplantation at our biennial international small bowel transplant symposium. The International Intestinal Transplant Registry (IITR), which was founded by David Grant and until now managed at the University of Toronto, has been the repository for the data that informed these updates. As intestinal transplant volume has grown and our Association has matured, Dr. Grant encouraged the transition of responsibility for the Registry to the Scientific Committee of our Association. The Council agreed and examined several proposals for this transition to a new and sustainable location and structure. We are proud to announce a new partnership between the IRTA and the Terasaki Institute for the maintenance of the historic functions of the Registry. In addition, the IITR is also now positioned to become a platform that may support multicenter trials, collaborations and innovation in order to move the field forward.

As we gain momentum with these transitions, we anticipate more substantial collaborations that will undoubtedly lead to new discoveries that are not possible from the observations of single center small case series. This is an exciting time for our Association and we look forward to seeing you in New York next year!  

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi